title: Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data.
abstract: This study of patients with remitted chronic schizophrenia in an aftercare clinic was designed to test whether such patients require maintenance antipsychotic medication. A previous report showed that the group receiving active medication, fluphenazine decanoate and oral fluphenazine, had far fewer relapses; but the former group had a high incidence of akinesia. This present report presents rating scale data substantiating these two findings: (1) patients terminated on clinical grounds because of a schizophrenic relapse showed rating scale changes consistent with that diagnosis; and (2) the patients removed due to severe akinesia showed a worsening on items selected a priori to measure akinesia, and when compared to survivors on the same items, showed significant differences--thus confirming our clinical judgments.
mesh_terms: D000284:Administration, Oral; D000359:Aftercare; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002908:Chronic Disease; D004311:Double-Blind Method; D005476:Fluphenazine / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007267:Injections; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012075:Remission, Spontaneous; D012559:Schizophrenia / Q000517:prevention & control*
chemical_list: D010919:Placebos; D005476:Fluphenazine